Retatrutide Availability in 2026: Can You Get It Yet?

Here is the whole retatrutide availability picture in one paragraph. As of August 11, 2026, retatrutide is not available as a normal prescription or pharmacy product anywhere in the world. No pharmacy has an approved product to fill. No doctor can write an ordinary retatrutide prescription. Two verified, currently documented paths to authentic Lilly-made retatrutide exist right now: a Lilly clinical trial, or a narrow expanded access request that your treating physician files for you. Lilly plans to ask the FDA for approval in the first quarter of 2027.

That's the short answer. Here's the part almost nobody tells you.

We pulled the actual records — Lilly's own trial pages, the government trial registry, and FDA's enforcement documents. When we checked on August 11, exactly one Phase 3 retatrutide study was labeled "enrolling" on both of Lilly's own trial interfaces. One more showed two different statuses on two different Lilly pages, at the same time. And the expanded access program that made headlines on August 3 has been sitting in the public trial registry since June 5 — with an eligibility rule some early coverage left out.

So the real retatrutide availability question isn't "is it approved." Everyone answers that. The real question is: which door is open for me, as of what date, and what do I say to my doctor?

That's what this page does.

This page is for you if

• You want to know if you can get real retatrutide right now
• You saw the "early access" headlines and want to know if that means you
• You want to find a trial that's actually enrolling, not one that closed in April
• A clinic, telehealth site, or online seller offered you retatrutide and something felt off
• You're deciding whether to wait for it or start something you can actually get

This page is not for you if

• You want dosing, mixing, or injection instructions — we don't publish those for an unapproved drug
• You want a review of online sellers — we don't rank them or link to them
• You want the full weight-loss numbers → see Retatrutide Weight Loss Results
• You want the side effect data → see Retatrutide Side Effects

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Retatrutide availability, path by path: what "available" actually means

Short answer: The word "available" is being used for at least ten different things in retatrutide search results, and only two of them are verified, currently documented medical access routes to authentic Lilly-made retatrutide. As of August 11, 2026, retatrutide has no approved prescription form, no retail pharmacy stock, no lawful U.S. compounded version, and no announced commercial price. A clinical trial and a physician-requested expanded access pathway are the two verified doors.

Read this table first. It answers the question every way people usually mean it so you don't have to search ten more times.

What changed this summer: Lilly's expanded access record was first posted publicly on June 5, 2026. On August 3, 2026, Lilly confirmed that it was actively reviewing requests from doctors under the program. That is a real change. It is not a launch, not a waitlist, and not a program most people will qualify for.

The honest part: we can't get you an ordinary retatrutide prescription. Nobody can legally sell you one today. And the expanded access door is narrow enough that most people reading this won't fit through it — the posted record requires a BMI of 35 or higher, adherence to and tolerance of the highest available dose of chronic weight-management therapy without enough benefit, two or more serious complications already under treatment, no workable trial, and a discussion of all standard options including bariatric surgery. If that's not you, this page won't end with a way to get retatrutide. It'll end with something more useful: the two verified doors, the exact facts to hand your doctor, and an honest read on whether waiting until 2027 or 2028 is worth it for your situation.

➡️ See which retatrutide path fits your situation →

Which retatrutide route could apply to you?

What should you do if retatrutide is not available to you?

The right GLP-1 treatment path isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a route that fits those answers. It asks up to nine short questions, is free, takes about a minute, and does not require signup.

One thing to be clear about: that tool does not match anyone to retatrutide, research peptides, or unapproved sellers. It exists for the treatments you can legally start today, subject to a licensed clinician's decision.

➡️ Find an available GLP-1 path →

Is retatrutide FDA approved?

Short answer: No. Retatrutide (also called LY3437943) is an investigational drug, which means it is still being tested and has not been approved by the FDA or any other regulator in the world. Eli Lilly said on July 23, 2026 that it plans to submit its U.S. application in the first quarter of 2027.

"Investigational" is a specific status, not a soft one. It means the drug can only be given inside a research study or through a legal pre-approval pathway such as expanded access. There is no FDA label, no approved dose, no retail pharmacy stock, and no approved commercial product.

You'll also see retatrutide called "GLP-3." That nickname isn't a real drug class. There is no third GLP receptor. Retatrutide is a once-weekly shot that acts on three receptors at once — GIP, GLP-1, and glucagon — so people started calling it a triple agonist, and "GLP-3" stuck. The nickname is scientifically inaccurate but common. If a seller uses it in a product name to make an online vial sound official, slow down.

Can a doctor prescribe retatrutide off-label?

No. Off-label prescribing applies to an approved drug used in a way that is not on its approved label. Retatrutide has no approval and no label, so there is nothing to prescribe "off" of.

Is Right to Try a third way to get retatrutide?

Not one we can verify as usable. Federal Right to Try can apply to certain patients with a life-threatening disease or condition who have exhausted approved options and cannot join a trial. But the manufacturer still has to agree to provide the investigational drug, and it is not required to do so.

Lilly publishes a general expanded access policy and retatrutide has a public expanded access record. We found no published Lilly retatrutide Right to Try route, contact process, or eligibility protocol. So we are not going to turn a federal law into a fake third door.

Who qualifies for retatrutide expanded access?

Short answer: Lilly's expanded access program for retatrutide is registered publicly as NCT07629401, and its posted criteria require all five of the following: age 18 or older, refractory obesity with a BMI of 35 or higher despite adherence to and tolerance of the highest available dose of chronic weight-management therapy, two or more serious or life-threatening obesity-related complications currently being treated, inability to join a retatrutide or comparable trial, and a documented discussion of all standard options including bariatric surgery. Meeting the criteria does not guarantee access.

First, what expanded access even is. It's sometimes called compassionate use. It's a narrow, legal exception that lets a patient get an unapproved drug outside a study when the patient has a serious or life-threatening condition, no comparable or satisfactory approved option, and no practical way to receive the drug through a trial.

Some early coverage of the August announcement described four criteria. The public registry record lists five, and the one that kept getting dropped was the BMI number.

Here are the posted criteria in plain English, next to what Lilly's record actually says.

The only listed exclusion is a medical reason retatrutide would be unsafe for you.

Why that fourth rule matters more than the early coverage suggested. The registry says a lack of a reasonably accessible enrolling site can satisfy it. And when we checked Lilly's own trial listings on August 11, almost nothing was clearly open. For someone with no reachable site that is actually screening, criterion four may be easier to document than medical ineligibility.

What the record also says out loud: availability depends on geography, product supply, and an individual eligibility check. So even a perfect match on paper is not a yes.

➡️ Use the one-page checklist below with your doctor →

Retatrutide expanded access checklist for your doctor

Print this section or copy it into your patient portal message. It does not create eligibility. It keeps the conversation from starting with a vague "Can I get retatrutide?"

• [ ] Current BMI: ________ Date measured: ________
• [ ] Current chronic weight-management therapy: ________
• [ ] Highest available dose taken: ________
• [ ] Dates at that dose: ________ to ________
• [ ] How adherence was documented: ________
• [ ] How tolerance was documented: ________
• [ ] Why the response was not enough: ________
• [ ] Serious complication 1: ________ Current treatment: ________ Treating clinician: ________
• [ ] Serious complication 2: ________ Current treatment: ________ Treating clinician: ________
• [ ] Retatrutide or comparable trials checked: study numbers, sites, and dates: ________
• [ ] Why each trial is not workable: protocol exclusion, failed screening, closed enrollment, or no reasonably accessible site: ________
• [ ] Standard options, including bariatric surgery, discussed: ________
• [ ] Known contraindications or safety concerns reviewed: ________
• [ ] Expanded access record: NCT07629401
• [ ] Lilly physician contact: 1-800-Lilly-Rx (1-800-545-5979) in the U.S.; local Lilly medical office outside the U.S.
• [ ] Unanswered cost questions: drug, visits, labs, monitoring, travel, and how long treatment could continue

How does a doctor request retatrutide expanded access?

Short answer: The request must come from the treating physician, not the patient. Lilly's registry record directs U.S. doctors to contact the company through the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979), and states that patients and caregivers should be directed to their own physician rather than contacting Lilly. Lilly's general expanded access policy says it responds within five business days after receiving a request with the required medical information, and that regulatory authorization is still required before it can ship an investigational medicine.

Five steps, in order:

1. Start with the doctor who's actually treating you. Not a clinic that advertises peptides. The request needs someone who knows your chart, your medication history, and the conditions you're being treated for — because those are exactly what Lilly reviews.

2. Rule out a trial together. Criterion four requires it. Your doctor has to be able to say why a study isn't possible — wrong condition, failed screening, closed enrollment, or no site you can reasonably reach.

3. Your doctor contacts Lilly. The registry record points physicians to the Lilly Answers Center. This is a physician request. Please don't call it yourself — the record specifically says patients should be directed back to their doctor, and a patient call cannot start the request.

4. Lilly reviews. Its policy says a response comes within five business days once it has the request and complete medical information. Read that carefully: a response is not an approval. The five-business-day clock starts after the required information arrives.

5. Regulatory and ethics steps happen after. Lilly cannot ship an investigational medicine until the regulator authorizes it. In the U.S., the treating physician, manufacturer, institutional review board, and FDA can all have roles. You'll sign a consent form that explains this is not an approved treatment.

The honest odds, from doctors who tried it. Before the program was public, physicians who applied for patients told STAT they waited weeks without a substantive answer. Spencer Nadolsky, DO, and Mike Albert, MD, of the obesity clinic Vineyard said they had applied for several patients who had not responded well enough to Lilly's approved medicine. Nadolsky said one patient received only a preliminary qualification — and only after a reporter contacted Lilly. That history explains why some doctors were skeptical when the program became public.

There's also a structural fact worth knowing, because it explains why this feels like a locked door. The 21st Century Cures Act requires companies to publish an expanded access policy, but it does not require a company to provide its investigational drug to any individual patient. The manufacturer is the first gate. If Lilly says no, FDA cannot force it to provide supply. If Lilly says yes, regulatory and ethics steps still follow.

Questions worth asking your doctor before you both invest the effort:

• Why isn't a trial realistic for me specifically?
• Which weight-management therapies have I tried, at what doses, for how long?
• Did I adhere to and tolerate the highest available dose, as the posted record requires?
• Which two serious complications are being treated right now?
• Who pays for the drug, the visits, the labs, the monitoring, and the travel? Nobody has published that.
• What's the plan while the request is under review?
• What do we do if the answer is no?

Are any retatrutide clinical trials still enrolling?

Short answer: Almost none. When The RX Index checked Lilly's trial pages and the public registry on August 11, 2026, one retatrutide study — SYNERGY-Outcomes (NCT07165028), a liver study — was labeled enrolling on both of Lilly's own interfaces. TRIUMPH-7 (NCT07035093) showed conflicting statuses on two Lilly pages at the same time. Every other Phase 3 study in the register below was closed to new participants or had already reported results.

This is where the standard advice on page one of the search results falls apart. Almost every guide tells you to search the registry and filter for "recruiting." That is only a starting point now. Site status can lag, and even Lilly's own interfaces can disagree.

The full Phase 3 retatrutide study register, plus expanded access

Built from Lilly's own study pages and cross-checked against the linked registry records. Statuses checked August 11, 2026. "Total time" means the approximate time a participant remains in the study, not just the week of the main measurement. Statuses change — confirm the specific record and call the site before you make travel or treatment plans.

Three things in that table are worth stopping on.

TRIUMPH-9 has no placebo group

One reason people skip trials is the placebo. You sign up for a long study hoping for retatrutide and you might receive placebo instead. Fair concern.

TRIUMPH-9 is different. Its registry record lists three groups, and all three receive retatrutide — the study is comparing different speeds of dose ramp-up, not drug versus nothing. Estimated enrollment is 600 people, the study lasts about 113 weeks, and the main measurement is at week 104.

We checked, and it's closed to new participants as of the last status verification. So this isn't a door for you today. It matters for two reasons: it proves Lilly runs retatrutide studies without a placebo arm, and it is a design to watch for if a similar study opens.

TRIUMPH-7 has two official statuses at the same time

When we checked on August 11, Lilly's individual page for TRIUMPH-7 showed the study as enrolling. Lilly's main trial finder showed the same study as completed enrollment. Both are Lilly. Both were live on the same day.

We're not going to pick one and pretend. Here's what we'd tell a friend:

If TRIUMPH-7 looks like a fit — obesity or overweight plus long-running low back pain in the lower back or upper legs — call the specific study site and ask one question: are you screening new participants this week? Do not book travel, quit a medication, or change a treatment plan based on a website label — including Lilly's.

Publishing that conflict is not a weakness in this page. It's the reason to trust it. We checked two official sources instead of one.

The one study clearly labeled enrolling is a 4.5-year liver study

SYNERGY-Outcomes was labeled enrolling on both of Lilly's interfaces when we checked. It studies adults with high-risk MASLD — metabolic dysfunction-associated steatotic liver disease, the current name for fatty liver disease caused by metabolic problems. Participants get retatrutide, tirzepatide, or a placebo.

The commitment is real: roughly 4.5 years and about 30 study visits, plus liver fat and fibrosis findings required to get in.

That's not a workaround for someone who wants a weight-loss shot. It's a serious research commitment for someone with a serious liver condition. Which leads to the practical connection that matters here:

If the only retatrutide study clearly labeled open is a multi-year liver trial you don't qualify for, then "there is no reasonably accessible enrolling site" may be literally true — and that is one of the five expanded access criteria. Your doctor can document it.

The 90-day rule that can shut the door before screening

Here's the trap that can cost people a screening visit. Protocols differ, but the retatrutide study records we read exclude recent weight-loss medication use. TRIUMPH-9's record excludes anyone who has taken weight-loss drugs, including over-the-counter ones, within 90 days before screening. TRIUMPH-7 carries the same type of restriction.

Translation: if you're on Zepbound, Wegovy, or another weight-loss drug right now, those two protocols would not screen you until at least 90 days after your last use. Never stop a prescribed medicine to chase a trial slot without your prescriber and the study team.

Other common exclusions in the TRIUMPH-9 record:

• Body weight change of more than 5 kg (about 11 pounds) in the 90 days before screening
• Prior or planned weight-loss surgery
• Type 1 or type 2 diabetes, for that specific study
• Personal or family history of medullary thyroid cancer, or MEN-2 syndrome
• History of pancreatitis

TRIUMPH-7 also lists recent heart attack, stroke, hospitalization for unstable angina or heart failure, and Class IV heart failure among its exclusions.

Don't read that list as universal — every protocol writes its own. Read it as: the screening is strict, the record tells you the rules before you drive anywhere, and stopping your current medicine to chase a trial slot is a decision to make with a doctor, not a website.

➡️ Search the official retatrutide records on ClinicalTrials.gov →

Why isn't retatrutide approved yet if the trials worked?

Short answer: The clinical results are largely in — five Phase 3 retatrutide studies have reported positive results. But a positive trial is not a finished approval application. In its July 23, 2026 release, Lilly said it is completing the Chemistry, Manufacturing, and Controls data package required for a Biologics License Application and plans to submit in the first quarter of 2027.

This is the part that frustrates people the most, so let's be specific.

CMC stands for Chemistry, Manufacturing, and Controls. It's the enormous file that shows what the medicine is, how it is made, and how the company controls its purity, strength, and batch consistency. Not "does the drug work" — "can you make it reliably." The remaining work Lilly named publicly was completing that manufacturing and quality package.

Two details worth catching, because plenty of pages still get them wrong:

It's a BLA, not an NDA. A Biologics License Application is the pathway Lilly says it will use. A New Drug Application is a different pathway. Lilly's own release says BLA. Several guides still say "NDA expected late 2026" — that's two errors in one sentence.

Lilly says the clinical package can support submissions for three uses. The company named obesity, knee osteoarthritis pain, and obstructive sleep apnea. That does not mean one filing or one approval automatically covers every country or every use. Regulators decide what each application supports and what appears on each label.

When will retatrutide be available by prescription?

Short answer: No approval date or launch date has been set. Lilly plans to file in the first quarter of 2027. Using FDA's published review goals, a standard review points to roughly Q1–Q2 2028 and a priority review points to roughly Q3–Q4 2027 — and approval still isn't the same as pharmacy stock.

Every page you'll read picks one date and states it like a fact. We're going to show you the math instead, because the answer depends entirely on which review clock retatrutide gets.

Now the caveats, which are the actual value here:

Priority review isn't automatic. It's granted when FDA decides an application qualifies. Nobody at Lilly or FDA has said retatrutide will get it.

The national-priority route is real, and Lilly has used it. FDA approved Foundayo under the Commissioner's National Priority Voucher program 50 days after filing. No voucher has been announced for retatrutide. We looked. That's an absence of an announcement, not proof that one can never happen.

Review clocks can move. A major amendment, inspection issue, incomplete application, or manufacturing problem can extend a goal date. This table is math from published targets, not a promise.

One honest wrinkle about the math. For original BLAs, the PDUFA goal runs from a filing date that is usually about 60 days after FDA receives the application. That is why the table shows both the review clock and the rough time from submission.

And approval is not a pharmacy shelf. After an approval come labeling, manufacturing scale-up, distribution, and payer decisions. Lilly is building for that — it announced a $3.5 billion plant in Pennsylvania's Lehigh Valley for next-generation obesity drugs including retatrutide, with the site expected to be operational in 2031. That tells you something about long-term supply. It does not give you a 2027 launch date.

Our editorial read: if you need help with your weight in the next 12 months, retatrutide is not your plan. If you're medically stable and simply want the strongest option eventually, waiting is a legitimate choice — just make it a decision with a date attached, not a year of refreshing search results.

➡️ See whether waiting or starting now fits you →

Can retatrutide be compounded by a pharmacy or prescribed through telehealth?

Short answer: No lawful U.S. compounding path exists. FDA states directly that retatrutide cannot be used in compounding under federal law, because it is not a component of an FDA-approved drug and does not meet the federal bulk-substance conditions that could permit its use. A telehealth visit does not change those rules.

Two quick definitions, since these labels get used to make things sound legitimate:

• A 503A pharmacy is a patient-specific compounding pharmacy that mixes a medicine for one identified patient with a valid prescription while meeting section 503A conditions.
• A 503B outsourcing facility is a larger, FDA-registered facility that can make batches for clinics and hospitals while meeting section 503B conditions.

Both can do legal and useful work. Neither can legally compound retatrutide. Here's the reasoning from FDA's public statement and warning-letter analysis:

The three-key lock. For a 503A pharmacy to compound with a bulk ingredient, that ingredient must clear an applicable federal route. Retatrutide fails all three:

1. Is there an applicable USP or NF monograph? A published, official quality standard for the substance. No.
2. Is it a component of an FDA-approved human drug? No.
3. Is it on the 503A bulks list? No.

For a 503B outsourcing facility, there are two routes: the substance appears on the 503B bulks list, or the drug made from it appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing. Retatrutide meets neither route.

That's it. Every U.S. compounding door is shut, and it's shut by design, not by oversight. FDA states directly that retatrutide cannot be used in compounding under federal law. The agency has also warned telehealth companies for marketing unapproved retatrutide directly to consumers, warned ingredient distributors for selling it to compounders, and warned outsourcing facilities for repackaging it.

Four questions that end the conversation with any U.S. seller

If a clinic, pharmacy, or website offers you "compounded retatrutide," ask these. Written down, in order:

1. Which USP or NF monograph covers retatrutide?
2. Which FDA-approved drug is retatrutide a component of?
3. Which federal bulks list permits retatrutide — 503A or 503B?
4. If you claim the 503B shortage route applies, which approved retatrutide drug is on FDA's drug shortage list? Send me the official record.

The verified answers are no monograph, no approved-drug component, neither bulks list, and no approved retatrutide shortage listing. A prescription does not turn an unlawful compounded retatrutide product into an FDA-approved or federally compliant drug.

Red-flag phrases, in case you're mid-conversation right now: "pharmacy-grade retatrutide," "FDA-compliant retatrutide," "generic retatrutide," "same as Lilly's," "compounded GLP-3," "prescription research peptide," "available in all 50 states." A licensed clinician being involved does not make an unlawful compounded retatrutide product legal.

Can you buy retatrutide online safely?

Short answer: No. Products sold online as retatrutide or "research use only" peptides are not approved prescription medicine, and a seller's label does not establish the identity, purity, strength, or sterility of the vial in your hand.

We're not going to lecture you. If you've already bought a vial, you're one of a lot of people, and there's a section below for you.

Here's what's actually documented.

FDA has drawn a bright line. It says retatrutide has not been found safe and effective for any condition, cannot be used in compounding under federal law, and has been marketed by telehealth companies and ingredient sellers despite that status.

A government health department has documented liver injury. Victoria's Department of Health in Australia reported six cases of acute liver injury since January 2026 in people who used unapproved products labelled Retatrutide, Reta, R-10, or R-20, bought online, from friends, or through social media. Officials said contaminants might be contributing and the investigation was still ongoing.

Sit with that last detail. Not "authentic retatrutide caused liver injury." The products were unapproved and their contents were still under investigation. These cases show that serious harm was reported after people used products carrying the retatrutide name. They do not prove a Lilly trial product caused the injuries.

Why a certificate of analysis doesn't fix it. A seller-supplied lab report tests a sample the seller chose. It doesn't establish what's in your specific vial, whether it stayed at the right temperature in transit, whether it's sterile, whether the strength on the label matches what's inside, or whether the report belongs to your batch. It's a document, not a chain of custody.

If you already took something labeled retatrutide

No judgment, and no dosing advice. Three things:

1. Tell your treating clinician exactly what you used, when, and how much. Bring the vial, packaging, label, receipt, order page, and any photos. They cannot help you well with half the story.
2. For severe or fast-worsening symptoms, get urgent help. In the U.S., Poison Control is 1-800-222-1222, free and available 24/7. In Victoria, Australia, the Poisons Information Centre is 13 11 26. Call emergency services for an emergency.
3. Report it. FDA's MedWatch program takes consumer reports, and those reports are how patterns get found.

For what symptoms mean and how they compare to Lilly's trial data, see our Retatrutide Side Effects page. One caution as you read it: an unknown vial may not contain authentic retatrutide at the stated strength, so trial side-effect rates may not describe what you took.

Is retatrutide available in the UK, Canada, or Australia?

Short answer: No. Retatrutide has not been approved by any regulator in any country as of August 11, 2026. Lilly has said it believes the clinical package can support global submissions, but no country has an approved commercial product, an approved price, or routine pharmacy availability. Australia currently has an active health alert about liver injury linked to unapproved products labelled retatrutide.

Trials run in multiple countries — the studies we reviewed list sites across the United States, Canada, the United Kingdom, Argentina, Australia, Mexico, Spain, Poland, India, Brazil, China, and others. A trial site in your country is not the same as availability in your country.

Two practical notes:

• An import rule does not turn an online vial into approved medicine. Check your national regulator before moving an unapproved drug across a border. Australia has an active liver-injury alert tied to unapproved products labeled retatrutide.
• Outside the U.S., expanded access runs through local channels. Lilly directs physicians to their local Lilly medical office rather than the U.S. line. The five criteria on the U.S. registry record are U.S. criteria and should not be assumed to be the rules everywhere.

Should you wait for retatrutide, or start something you can get now?

Short answer: Waiting is reasonable for someone who is medically stable and simply wants the strongest future option. It is not a treatment plan for someone whose health is getting worse, because retatrutide's approval date, launch date, price, and insurance coverage are all still unknown. FDA-approved medicines are available today from licensed prescribers, and starting one does not lock you in forever. A later switch would be a decision with your prescriber.

Here's the trade-off stated honestly, because you deserve the real version.

The approved drugs lose on the headline number. Retatrutide's top dose produced about 28.3% average weight loss over 80 weeks in TRIUMPH-1 under the efficacy estimate, and that's higher than the headline averages for anything approved today. If the biggest possible number is the only thing you care about, retatrutide is the drug you want, and you will be waiting until at least 2027 — possibly 2028 — with no guarantee.

But when you compare the drugs on the same measuring stick, using the treatment-regimen estimate that counts people by the group they were assigned to even if treatment changed or stopped, the lead over the best approved option is roughly 3.3 percentage points after adjusting each trial for its placebo result — not the 6 to 14 points the headlines imply.

3.3 points instead of ten. That's the honest size of the lead on this one same-estimand, placebo-adjusted comparison — not a head-to-head verdict. The trials had different lengths, populations, and protocols. TRIUMPH-5 is the direct retatrutide-versus-tirzepatide study that can answer the comparison more cleanly. We show the full math on our Retatrutide Weight Loss Results page.

And the smaller number comes with things a vial in the mail can never give you: an approved label, known manufacturing controls, a pharmacist who checks your other medications, a dose that's actually what it says, a prescriber who adjusts treatment, and a refill that shows up. A smaller number you can trust beats a bigger number you can't.

Find yourself in this table

Provider-stated claims versus what we verified on August 11, 2026

The table below is not a retatrutide comparison. These are routes for approved treatments that can exist now if a clinician finds them appropriate.

If cost is what pushed you toward online vials, do this one free thing first. Ro has a coverage checker for the Ozempic pen, Wegovy pen, and Zepbound pen. It asks for the information on your insurance card and emails a personalized report. Ro Body membership starts at $39 for the first month, then $74–$149 per month depending on the plan, with medication billed separately.

➡️ Check what your insurance covers with Ro → (affiliate link)

If you'd rather pick your own prescriber, Sesame lets you choose a provider and publishes its subscription pricing. Its annual plan starts at $59 per month, and its month-to-month plan is $99 per month, with medication billed separately.

➡️ See Sesame's current weight-loss program pricing → (affiliate link)

And if you're considering a compounded medication instead, that's a different conversation, not a retatrutide workaround. A patient-specific clinical need can matter; a lower price by itself does not make an essentially copied drug lawful. Compounded drugs are not FDA approved, and lawful availability depends on the ingredient, current federal conditions, the patient-specific need, the pharmacy, and the prescriber's decision. We will never present a compounded drug as equivalent to an FDA-approved medicine. Start with The RX Index's Find My GLP-1 Path tool and tell it your preference.

How much will retatrutide cost, and will insurance cover it?

Short answer: Lilly has not announced a price for retatrutide, and there is no routine insurance coverage for a commercial retatrutide product because no approved product exists to cover. Any specific monthly retatrutide price shown online today is either a guess or the price of an unapproved product. Retatrutide is not included on the current CMS Medicare GLP-1 Bridge product list.

That last point is useful, but it needs to be stated correctly.

The Medicare GLP-1 Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2027. It gives eligible Medicare Part D beneficiaries access to listed products for weight management under the program's rules, with a $50 copay for eligible use. CMS currently lists Foundayo, Wegovy injection and tablets, and Zepbound KwikPen.

Retatrutide is not named in it. That tells you nothing certain about a future retatrutide price. It proves only that current CMS programs name products and formulations; they do not automatically include every future drug in a class.

What has to happen before anyone can answer your cost question:

1. Lilly submits the application
2. FDA accepts it for review
3. FDA makes a decision
4. An approved label and approved uses are published
5. Lilly announces a list price, cash-pay route, and any savings programs
6. Insurers, employers, Medicare, Medicaid, and pharmacy benefit managers make their own decisions
7. Prior-authorization rules and formularies go live

That's seven steps, and step one hasn't happened. We won't publish a fake number to fill the gap, and we'd be careful with any page that does.

What we actually verified

Short answer: The RX Index built this page by reading primary records rather than summarizing search-result claims. We checked FDA's compounding position and warning-letter language, Lilly's July 23, 2026 announcement, Lilly's expanded access policy, the public registry record for Lilly's retatrutide expanded access program, and the Phase 3 records listed in the study register. Where two official sources disagreed, we published the disagreement instead of picking one.

Checked August 11, 2026:

• FDA's public statement on unapproved GLP-1 drugs, including the direct language that retatrutide cannot be used in compounding under federal law
• FDA warning letter 715883, dated September 9, 2025, for the specific 503A and 503B reasoning
• FDA's published standard, priority, and national-priority review timelines
• Lilly's July 23, 2026 announcement, for the CMC package and Q1 2027 BLA plan
• Lilly's retatrutide FAQ, for investigational status, receptor targets, and the absence of a commercial price
• Lilly's expanded access policy, for the physician-initiated process and the five-business-day response commitment
• The public expanded access record NCT07629401, for the five eligibility criteria, June 5 first-posted date, and request mechanism
• Individual Phase 3 records for TRIUMPH-1 through TRIUMPH-9, TRIUMPH-Outcomes, SYNERGY-Outcomes, and TRANSCEND-T2D-1 through -3
• Lilly's individual trial pages and main trial finder, which is how we found the TRIUMPH-7 conflict
• FDA's Right to Try page, to confirm that the law does not force a manufacturer to provide an investigational drug
• Victoria's June 19, 2026 health alert, for the six liver-injury cases tied to unapproved products labelled retatrutide
• CMS's Medicare GLP-1 Bridge page, for the July 1, 2026 start, December 31, 2027 end, $50 copay, and named products
• Ro's live pricing and insurance-checker pages
• Sesame's live weight-loss program and subscription-pricing page
• The RX Index's live Find My Path explanation, for up to nine questions, free use, roughly one minute, and no signup

Conflicts we found and did not hide:

• TRIUMPH-7 showed as enrolling on Lilly's individual study page and as completed enrollment on Lilly's main trial finder on the same day
• Lilly's older retatrutide FAQ says trials are the only path to authentic retatrutide; the newer public expanded access record and August confirmation created a second verified path. The older FAQ had not caught up when we checked.

What we could not verify, and are not claiming:

• Any FDA approval date, launch date, or commercial price
• Whether Lilly will seek or receive priority review or a national priority voucher for retatrutide
• Who pays for the drug, visits, labs, monitoring, or travel under expanded access, or how long access continues
• How many expanded access requests Lilly has approved
• Whether any particular TRIUMPH-7 site is screening this week without calling that site
• Any usable Lilly retatrutide Right to Try process

What we did not do: we did not buy an online product, enroll in a study, or claim any firsthand experience with retatrutide. This page has no medical reviewer. We report what regulators and the manufacturer have published, we link to it, and we date it. If something here is wrong, tell us and we'll fix it and log the change.

Retatrutide availability FAQ

Is retatrutide available in the United States? Not as a normal prescription or pharmacy product. As of August 11, 2026, the two verified paths to authentic Lilly-made retatrutide are a qualifying clinical trial or a treating-physician expanded access request under registry record NCT07629401.

Is retatrutide FDA approved? No. It is investigational. Lilly plans to file a U.S. Biologics License Application in the first quarter of 2027.

Can my doctor prescribe retatrutide off-label? No. Off-label prescribing applies to approved drugs used in unapproved ways. Retatrutide has no approval and no label, so there is nothing to prescribe off of.

Can a telehealth company prescribe retatrutide? Not as an ordinary prescription. A telehealth visit does not change federal approval or compounding rules. A legitimate clinician can discuss trials, expanded access, or approved medicines.

Can retatrutide be compounded? Not lawfully under current U.S. federal compounding law. FDA states that retatrutide cannot be used in compounding. It is not a component of an approved drug and does not satisfy the applicable bulks-list or drug-shortage route.

Who qualifies for retatrutide expanded access? All five posted criteria must be met: age 18+, BMI 35 or higher with refractory obesity despite adherence to and tolerance of the highest available dose of chronic weight-management therapy, two or more serious obesity-related complications currently being treated, inability to join a retatrutide or comparable trial, and a documented discussion of all standard options including bariatric surgery.

Can I apply for retatrutide expanded access myself? No. The registry record states that requests are initiated by the treating physician and that patients and caregivers should be directed to their own doctor rather than contacting Lilly.

How long does Lilly take to respond to an expanded access request? Lilly's policy states that it responds within five business days after receiving the request and required medical information. A response is not an approval, and regulatory authorization is required before Lilly can ship an investigational medicine.

Does expanded access mean retatrutide launched? No. It's a narrow pre-approval exception for individual patients. It is not routine prescribing, pharmacy availability, or a consumer program.

Is Right to Try another retatrutide route? Federal Right to Try exists for certain patients with life-threatening conditions, but the manufacturer is not required to provide the drug. We found no published Lilly retatrutide Right to Try process, so it is not a verified practical third door.

Are any retatrutide trials enrolling right now? When we checked on August 11, 2026, SYNERGY-Outcomes (NCT07165028), a high-risk MASLD study, was labeled enrolling on both of Lilly's interfaces. TRIUMPH-7 (NCT07035093) showed conflicting Lilly statuses. The other Phase 3 records in the table were closed to new participants or had reported results.

Will I get a placebo in a retatrutide trial? In many of them, it's possible. TRIUMPH-3 randomized participants 1:1:2 across two retatrutide doses and placebo, meaning about half received placebo. TRIUMPH-9 is the exception in the table — all three of its groups receive retatrutide — but enrollment is closed.

Can I join a trial if I'm currently taking Zepbound or Wegovy? Not immediately under the TRIUMPH-7 and TRIUMPH-9 rules we checked. Both exclude recent weight-loss drug use within 90 days before screening. Never stop a prescribed medicine to chase a trial slot without talking to your prescriber and the study team.

When will retatrutide be in pharmacies? No date exists. Applying FDA's published review goals to a Q1 2027 filing points roughly to Q3–Q4 2027 under priority review or Q1–Q2 2028 under standard review. No review designation has been announced, and approval is not the same as immediate pharmacy stock.

How much will retatrutide cost? Unknown. No commercial price has been announced.

Will Medicare or insurance cover retatrutide? Not yet — there's no approved product to cover. Retatrutide is not on the current Medicare GLP-1 Bridge product list.

Is "research use only" retatrutide the same as what's in Lilly's trials? No verified equivalence exists. In six Australian cases of acute liver injury tied to unapproved products labelled retatrutide, health officials said contaminants might be involved while the products were still under investigation.

Is retatrutide the same thing as "GLP-3"? "GLP-3" is a scientifically inaccurate nickname, not a real drug class. Retatrutide acts on three receptors — GIP, GLP-1, and glucagon — and is properly described as a triple agonist.

Does retatrutide have a boxed warning? It has no FDA boxed warning because it has no FDA label at all. That's not reassurance — it's the absence of an approved rulebook. See GLP-1 Boxed Warnings for how approved products are labeled.

Still not sure which available GLP-1 path is right for you?

➡️ Get your personalized GLP-1 action plan →

The free tool asks up to nine short questions about your state, health history, medication and format preference, insurance or cash-pay preference, and timeline. It routes only to treatment paths that can legally exist today and still leaves the medical decision to a licensed clinician.

The RX Index may earn compensation from some providers shown by the tool. That never changes the five RX Index Score pillars — clinical legitimacy, care quality, transparency, access, and cost — or the route produced by your answers. The tool does not match anyone to retatrutide, research peptides, or unapproved sellers.

Sources

1. Eli Lilly — What to Know About Retatrutide (updated July 2026)
2. Eli Lilly — Retatrutide Successful in Two Additional Phase 3 Obesity Trials (July 23, 2026)
3. Eli Lilly — Expanded Access Policy
4. FDA — Expanded Access: Information for Patients
5. FDA — Right to Try
6. ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide, NCT07629401
7. Lilly Medical — Retatrutide Clinical Trials in Obesity or Overweight
8. ClinicalTrials.gov — Retatrutide study search, including every NCT record linked in the table
9. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
10. FDA — Warning Letter 715883, GLP-1 Solution (September 9, 2025)
11. FDA — PDUFA VII Performance Goals
12. FDA — Priority Review
13. FDA — Commissioner's National Priority Voucher Pilot Program
14. FDA — Foundayo Approval Under the National Priority Voucher Program (April 1, 2026)
15. Eli Lilly — TRIUMPH-1 Phase 3 Results
16. Eli Lilly — SURMOUNT-1 Tirzepatide Results
17. Eli Lilly — Pennsylvania Manufacturing Site Announcement
18. Victoria Department of Health — Toxicity Linked to Unapproved Product Labelled Retatrutide (June 19, 2026)
19. CMS — Medicare GLP-1 Bridge Information for Providers
20. Ro — Weight-Loss Program Pricing
21. Ro — GLP-1 Insurance Coverage Checker
22. Sesame — Online Weight-Loss Program
23. The RX Index — How Find My Path Works
24. STAT — Retatrutide Expanded Access Reporting (August 3, 2026)

Corrections: Found an error? Email [email protected]. We fix it and log the change below.

Change log

• August 11, 2026 — v1.0 published. Added the expanded access record NCT07629401 with all five posted requirements, including BMI 35. Published the unresolved TRIUMPH-7 status conflict. Added the complete Phase 3 access register, including the three TRANSCEND-T2D studies. Documented TRIUMPH-9's no-placebo design. Corrected “NDA, late 2026” to BLA, Q1 2027. Corrected CMS Bridge dates and product scope. Added a provider-stated-versus-verified table and removed unsupported retatrutide seller and poison-control statistics.

Related pages on The RX Index

• Retatrutide Weight Loss Results — every dose, both estimands, and the same-ruler comparison
• Retatrutide Side Effects — trial rates by dose and what an unknown online vial cannot tell you
• What Is Retatrutide? — how the triple agonist works
• Retatrutide vs Tirzepatide — the indirect evidence and what TRIUMPH-5 can settle
• Retatrutide vs Semaglutide
• How to Verify a Compounding Pharmacy License
• Find My GLP-1 Path — the matching tool for available treatment routes